STATEMENT OF WORK

Contractor: Medical Science and Computing, LLC.  
Title: SBIR-STTR TABA Consulting

Laboratory ID: OD/OER/SEED  
Interview Date: 

================================================================================

**Background and Introduction:**
The National Institutes of Health (NIH) Small Business Education and Entrepreneurial Development (SEED) office is providing third party technical and business assistance (TABA) to some Phase II awardees of the NIH Small Business (SBIR/STTR) Program. Medical Sciences Computing/Guidehouse (MSC/GH) is responsible for identifying and recruiting vendors to provide consulting services in the following areas: intellectual property, market analysis, regulatory strategy and interactions, and reimbursement strategy and interactions. Small businesses participating in this program will work with MSC/GH and NIH staff to develop and refine Scope of Work (SOW) statements to solicit vendor proposals. Interested vendors are encouraged to request clarification of the SOW during their proposal development. The total costs of any vendor provided consulting service may not exceed $50,000 USD.

**Company Overview**

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Fake Hats Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Support Requested</td>
<td>Regulatory Consult</td>
</tr>
<tr>
<td>CEO</td>
<td>Bob Sacamano</td>
</tr>
<tr>
<td>CTO (PI)</td>
<td>Elaine Benes</td>
</tr>
<tr>
<td>Company website</td>
<td><a href="http://www.FakeHats.net">www.FakeHats.net</a></td>
</tr>
<tr>
<td>Sponsoring NIH Component</td>
<td>NIDCD</td>
</tr>
<tr>
<td>Technology Summary</td>
<td>Small molecule therapeutic (PES-456) is being developed as a first line therapy for Purple Ear Syndrome</td>
</tr>
<tr>
<td>Major market(s)</td>
<td>Purple Ear Syndrome patients (400,000 world-wide)</td>
</tr>
<tr>
<td>Technology stage</td>
<td>Pre-clinical safety &amp; efficacy with lead compound</td>
</tr>
<tr>
<td>Primary regulatory path</td>
<td>Orphan Indication, NDA (New Drug Application)</td>
</tr>
</tbody>
</table>

**Context of Service Request:**
Fake Hats Co. needs assistance with the development of an initial FDA interaction and submission of a new IND file to support the development of its first therapeutic molecule PES-456. PES-456 is being developed to resolve the symptomology of Purple Ear Syndrome – a condition where excessive blood flow to the tympanic membrane results in a characteristic purple color and which impacts the lives of effected people in one or more of the following ways: difficulty hearing; tinnitus; inability to “clear” ears during changes in altitude (leading to increased potential for ruptured ear drums); and challenges in balance (due to unequal pressure in eustachian tubes). Purple Ear Syndrome is an intermittent condition that can affect one or both ears, individually or simultaneously.
Fake Hat Co. has not had any documented interactions with the US FDA, though we have spoken with FDA representatives at scientific meetings and were guided to several relevant and informative guidance documents. We also met with the regulatory team at NIH to discuss possible pathways and used information from the following documents to guide our manufacturing and early animal studies:

- [Current GMP for Phase 1 Investigational Drugs](#)
- [ICH Q6A Specifications: Test procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances](#)
- [ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients](#)
- [ICH Q7 QandAs Questions and Answers: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients](#)
- [ICH S1B-R1 Testing for Carcinogenicity of Pharmaceuticals](#)
- [FDA Guidance Rare Diseases Natural History Studies](#)

We are in the final stages of engaging a CRO to conduct our IND enabling P/T studies and anticipate submitting our IND by Q2 next calendar year. We are seeking regulatory support through the TABA Consulting Services program to assist in the development and submission of our IND, including drafting SAD/MAD clinical protocols.

**Deliverables and Reporting Requirements:**

The expected deliverable for this program is submission of our IND to the appropriate FDA Office and allowance of our clinical trial. Interim milestones to achieve this deliverable might include:

- An analysis of documentation developed by Fake Hats to support the IND submission
- Review of data provided by the CRO performing the IND enabling P/T studies to ensure the data they will provide is sufficient to support the review of the IND file
- Collaborative development of an IND application for PES-456
- Development of an Investigators Brochure to support the Phase 1 trials for PES-456
- Successful submission of the IND for PES-456
- Collaborative development of response to reviewer comments during the IND review cycle

**Vendor Qualifications:**

- Recent experience (within the past 3 years) working with the relevant FDA review division
- Extensive expertise successfully submitting documents to FDA for small molecules
- Experience submitting INDs for auditory therapeutics